Get the Stockscreener App
2.85
2.06%
-0.06
Anixa Biosciences Inc stock is currently priced at $2.85, with a 24-hour trading volume of 73,925.
It has seen a -2.06% decreased in the last 24 hours and a -6.56% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $2.94 pivot point. If it approaches the $2.82 support level, significant changes may occur.
Previous Close:
$2.91
Open:
$2.92
24h Volume:
73,925
Market Cap:
$90.91M
Revenue:
-
Net Income/Loss:
$-10.74M
P/E Ratio:
-8.1429
EPS:
-0.35
Net Cash Flow:
$-6.53M
1W Performance:
-5.00%
1M Performance:
-6.56%
6M Performance:
-3.39%
1Y Performance:
-16.91%
1D Range:
$2.83
$2.92
52W Range:
$2.75
$5.13
Anixa Biosciences Inc Stock (ANIX) Company Profile
Name
Anixa Biosciences Inc
Sector
Industry
Phone
408-708-9808
Address
3150 Almaden Expressway, Suite 250, San Jose
Anixa Biosciences Inc Stock (ANIX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-23-22 | Initiated | Chardan Capital Markets | Buy |
| Apr-12-21 | Initiated | H.C. Wainwright | Buy |
Anixa Biosciences Inc Stock (ANIX) Latest News
Anixa Biosciences, Inc. (NASDAQ:ANIX) Short Interest Update - Defense World
Defense World
Should You Worry About Anixa Biosciences, Inc.'s (NASDAQ:ANIX) Cash Runway? - Yahoo Lifestyle UK
Yahoo Lifestyle UK
Short Interest in Anixa Biosciences, Inc. (NASDAQ:ANIX) Grows By 14.3% - MarketBeat
MarketBeat
Anixa Biosciences (NASDAQ:ANIX) Shares Down 1% - MarketBeat
MarketBeat
Anixa expands cancer vaccine collaboration with Cleveland Clinic - Pharmaceutical Technology
Pharmaceutical Technology
Anixa expands cancer vaccine collaboration with Cleveland Clinic - Pharmaceutical Technology
Pharmaceutical Technology
Anixa Biosciences Inc Stock (ANIX) Financials Data
Anixa Biosciences Inc (ANIX) Net Income 2024
ANIX net income (TTM) was -$10.74 million for the quarter ending January 31, 2024, a +11.12% increase year-over-year.
Anixa Biosciences Inc (ANIX) Cash Flow 2024
ANIX recorded a free cash flow (TTM) of -$6.53 million for the quarter ending January 31, 2024, a +10.34% increase year-over-year.
Anixa Biosciences Inc (ANIX) Earnings per Share 2024
ANIX earnings per share (TTM) was -$0.34 for the quarter ending January 31, 2024, a +17.07% growth year-over-year.
Anixa Biosciences Inc Stock (ANIX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| KUMAR AMIT | Chief Executive Officer |
Mar 15 '24 |
Buy |
3.22 |
30,000 |
96,600 |
491,925 |
| Baskies Arnold M | Director |
Mar 15 '24 |
Buy |
3.63 |
10,000 |
36,300 |
110,000 |
| Titterton Lewis H jr | Director |
Oct 10 '23 |
Option Exercise |
2.58 |
16,000 |
41,200 |
823,028 |
| KUMAR AMIT | Chief Executive Officer |
Jul 31 '23 |
Sale |
3.57 |
11,800 |
42,126 |
461,925 |
| KUMAR AMIT | Chief Executive Officer |
Jul 28 '23 |
Option Exercise |
2.58 |
40,000 |
103,000 |
502,100 |
| Titterton Lewis H jr | Director |
Jul 27 '23 |
Option Exercise |
2.58 |
120,000 |
309,000 |
894,070 |
| Catelani Michael | President, COO & CFO |
Jul 20 '23 |
Buy |
3.64 |
5,500 |
20,020 |
26,655 |
About Anixa Biosciences Inc
Anixa Biosciences, Inc. develops, acquires, and licenses emerging technologies in the areas of biotechnology. The company develops Cchek, a platform for non-invasive blood tests for the early detection of various cancers, including breast, lung, colon, melanoma, ovarian, liver, thyroid, pancreatic, appendiceal, uterine, osteosarcoma, leiomyosarcoma, liposarcoma, vulvar, and prostate cancer. It also develops immuno-therapy drugs for the treatment of cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was founded in 1982 and is based in San Jose, California.
0.77%
1.20%
Cap:
|
Volume (24h):